Stock KALV KALVISTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
12.17 USD -0.08% Intraday chart for KalVista Pharmaceuticals, Inc. +16.02% -0.65%
04-22 Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors CI
04-15 Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024. CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO
KalVista Pharmaceuticals, Inc. Announces Board Changes
KalVista Pharmaceuticals, Inc. Announces Chief Executive Officer Changes
Kalvista Pharmaceuticals Insider Sold Shares Worth $613,205, According to a Recent SEC Filing
Kalvista Pharmaceuticals Insider Sold Shares Worth $598,661, According to a Recent SEC Filing
Kalvista Pharmaceuticals Insider Sold Shares Worth $422,827, According to a Recent SEC Filing
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
KalVista Pharmaceuticals' Phase 3 Trial of Sebetralstat to Treat Hereditary Angioedema Meets All Endpoints; Shares Rise
KalVista meets main goals in late-stage trial for genetic disease
KalVista meets main goals in late-stage trial for skin condition treatment
Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema
Kalvista Pharmaceuticals Insider Sold Shares Worth $295,514, According to a Recent SEC Filing
Kalvista Pharmaceuticals Insider Sold Shares Worth $360,453, According to a Recent SEC Filing
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
KalVista Pharmaceuticals' Clinical Trial Reaches Milestone Needed to Complete Drug Candidate's Study
Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KALV Stock
  4. News KalVista Pharmaceuticals, Inc.
  5. Other languages